Prof. Andrés Ferreri | ICML 2017 | Extranodal Marginal Zone Lymphoma and the use of clarithromycin

Andrés Ferreri

Anne Villeneuve

Natasha Fort

Jun 22, 2017

Prof. Andrés Ferreri, from the San Raffaele Scientific Institute, Milan, IT, on the use of clarithromycin in Extranodal Marginal Zone Lymphoma:

Extranodal Marginal Zone Lymphoma and the use of clarithromycin

More about...

Andrés Ferreri Anne Villeneuve ICML 2017 Indolent B-cell lymphomas Marginal zone lymphoma Natasha Fort Rare lymphomas

Emerging clinical activity of REGN1979 in relapsed/refractory B-cell non-Hodgkin lymphoma

Doses of REGN1979 at 80mg or higher showed activity in more resistant tumors, such as in patients with R/R DLBCL.

Jul 4, 2019

Emerging clinical activity of REGN1979 in relapsed/refractory B-cell non-Hodgkin lymphoma

Doses of REGN1979 at 80mg or higher showed activity in more resistant tumors, such as in patients with R/R...

Jul 4, 2019

Lenalidomide approved by the FDA for follicular and marginal zone lymphoma

Lenalidomide, in combination with a rituximab product, has been approved by the FDA for previously treated follicular lymphoma and previously treated marginal zone lymphoma.

May 31, 2019

Lenalidomide approved by the FDA for follicular and marginal zone lymphoma

Lenalidomide, in combination with a rituximab product, has been approved by the FDA for previously treated follicular...

May 31, 2019

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox every month

First Name

Last Name

I agree to the Lymphoma Hub Terms & Conditions

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Prof. Andrés Ferreri | ICML 2017 | Extranodal Marginal Zone Lymphoma and the use of clarithromycin

Andrés Ferreri

Anne Villeneuve

Natasha Fort

Jun 22, 2017

More about...

Related articles

Jul 4, 2019

Jul 4, 2019

May 31, 2019

May 31, 2019

Newsletter